Key statistics
On Wednesday, Herantis Pharma Oyj (HRTIS:HEX) closed at 2.08, 73.33% above the 52 week low of 1.20 set on Apr 07, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 2.07 |
|---|---|
| High | 2.21 |
| Low | 2.05 |
| Bid | 2.08 |
| Offer | 2.08 |
| Previous close | 2.05 |
| Average volume | 40.55k |
|---|---|
| Shares outstanding | 26.50m |
| Free float | 20.71m |
| P/E (TTM) | -- |
| Market cap | 54.33m EUR |
| EPS (TTM) | -0.2417 EUR |
Data delayed at least 15 minutes, as of Mar 04 2026 17:00 GMT.
More ▼
Announcements
- Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096
- Herantis Pharma - Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease
- Herantis Pharma presents positive topline data for HER-096 in Phase 1b trial for people living with Parkinson’s disease
- Last patient visit completed on schedule in Phase 1b clinical trial of HER-096 for Parkinson’s disease
- First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease
More ▼
